Evicenter
Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
Manufacturer
Novartis Pharmaceuticals Corporation
Prescribing information
Kisqali (opens in a new tab)
Questions
57
Last updated

All questions

Guidelines: Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer

1 question · 2 sources

Guidelines

What do NCCN guidelines recommend for Kisqali in metastatic breast cancer?

Note: The first six passages are from the NCCN clinical flashcard (dated July 2025) that the expert guidelines page links, which reproduces NCCN Guidelines for Breast Cancer Version 4.2025 for ER- and/or PR-positive, HER2-negative recurrent unresectable or stage IV disease. The guideline lists other CDK4/6 inhibitor combinations in the same regimen lists. The last two passages are from the expert guidelines page, which cites Version 6.2026 (accessed July 30, 2026).